Our results showed that SCSP treatment significantly upregulated the expression level of apoptotic protein Bcl-2 (p < 0.01) and downregulated Bax, TNF-α, and caspases 3 and 9, thereby reversing the CTX-induced kidney damage. The gene discussed is BCL2; the disease is cerebrotendinous xanthomatosis.